A5071516345- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- SARS-CoV-2 and COVID-19 Research
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Breast Cancer Treatment Studies
- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Neuroblastoma Research and Treatments
- Cancer Risks and Factors
- Reproductive Biology and Fertility
- Cancer Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Influenza Virus Research Studies
- Melanoma and MAPK Pathways
- Pancreatic and Hepatic Oncology Research
- Family Support in Illness
- Neutropenia and Cancer Infections
- Chemotherapy-induced cardiotoxicity and mitigation
- Peptidase Inhibition and Analysis
- COVID-19 and healthcare impacts
Japanese Foundation For Cancer Research
2023-2024
The Cancer Institute Hospital
2024
Cancer Hospital and Research Institute
2024
Kobe University Hospital
2012-2022
Hyogo Prefectural Cancer Center
2019-2021
Kobe University
2012-2018
Utano Hospital
1994
e12589 Background: High-grade fevers exceeding 40°C after administration of carboplatin and paclitaxel have occasionally been observed in early triple-negative breast cancer (TNBC) patients who are receiving neoadjuvant therapy based on KEYNOTE-522 trial. Methods: We retrospectively reviewed 102 TNBC initiated KEYNOTE-522-based at our institution between October 2022 2024. assessed the incidence, timing, clinical course occurring within 24 hours plus paclitaxel, with or without...
12002 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event affecting patient quality of life. Limb cooling may help to prevent CIPN, but no phase 3 trials have confirmed its efficacy, and efficacy safety remain challenging. This trial determined if temperature-controlled limb could reduce CIPN in patients with breast cancer receiving weekly perioperative paclitaxel (PTX). Methods: multicenter, double-blind, randomized controlled (jRCT2032210115) assigned...
TPS632 Background: Triple negative breast cancer (TNBC) remains the most challenging phenotype of cancer. There is still an unmet clinical need for improving fine-tuning indications targeted treatments in this population. In TNBC, frequency germline BRCA (gBRCA) 1/2 mutations was reported to be up 19.5%. This has led promising strategies based on poly adenosine diphosphate (ADP)-ribose polymerase inhibitors that inhibit single-stranded DNA damage repair and/or modified chemotherapy...
Neuroendocrine carcinomas (NEC) of the female genital tract are aggressive and uncommon tumors, which usually involve uterine cervix ovary, seen very rarely in endometrium. Only less than 10 cases large cell NEC (LCNEC) endometrium have been reported literature their radiological findings not well described. We report here two pathologically proven LCNEC In both cases, body was enlarged tumor occupied part cavity. Endometrial mass exhibited heterogeneous high intensity on T2-weighted...
The development of skin rashes is the most common adverse event observed in cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such as erlotinib. However, pharmacological evidence has not been fully revealed.Erlotinib distribution was more heterogeneous than that normal skin, and contained statistically higher concentrations erlotinib adjacent superficial layer (229 ± 192 vs. 120 103 ions/mm2; P = 0.009 paired t-test). LC-MS/MS confirmed concentration...
In a phase III study of gemcitabine plus erlotinib for advanced pancreatic cancer conducted in Canada, the incidence interstitial lung disease (ILD) was 3.5 %. However, ILD reported as high 8.5 % Japanese II study. These results suggest influence ethnic factors association use with ILD. Here, we prospective to analyze relationship between human leukocyte antigen (HLA) alleles and patients receiving erlotinib. Patients were treated (1000 mg/m2; administered by intravenous infusion on days 1,...
Abstract Background Trastuzumab emtansine (T-DM1) treatment for human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer after taxane with trastuzumab and pertuzumab is standard therapy. However, strategies beyond T-DM1 are still in development insufficient evidence of their effectiveness. Here, we aimed to evaluate real-world choice efficacy treatments HER2-positive cancer. Methods In this multi-centre retrospective cohort study involving 17 hospitals, 325 female...
Abstract Background Carboplatin is a key drug for ovarian cancer. However, it sometimes induces hypersensitivity reactions (HSRs) that result in the discontinuation of treatment. Although various desensitization protocols have been reported previous retrospective studies, limited number prospective studies analyzed these protocols. Methods Patients with platinum-sensitive relapsed cancer who experienced carboplatin-induced HSRs were treated diluted solutions 1/1000, 1/100, 1/10 and an...
Background/Aim: Aldehyde dehydrogenase (ALDH) 1A1 is a well-known marker for cancer stem cells (CSCs), characterized by self-renewal capacity and multidrug resistance in breast cancer. We developed near-infrared turn-on fluorescence probe ALDH1A1, C5S-A, which suitable observing analyzing viable cells. Here, we demonstrated the utility of C5S-A CSC research using cell lines. Materials Methods: To evaluate concordance between conventional markers, sorted ALDEFLUOR-positive...
Inflammatory breast cancer (IBC) is the most aggressive form of primary cancer.A 40-year-old woman was referred to our hospital for evaluation an induration in right breast, suspected be cancer. The tumor diagnosed as estrogen receptor-negative, progesterone HER2-positive, T4dN3cM0 stage IIIc IBC with axillary lymph node metastasis. Rather than surgical intervention, we chose a systemic treatment approach pertuzumab, trastuzumab, and docetaxel (PTD) combination therapy which shown effective...
To confirm the reported transfer of multiple sclerosis (MS) by CSF cells, we injected cells from six MS patients in exacerbation stage into cisterna magna 18 severe combined immunodeficiency mice. No clinical neurologic abnormalities or light- electron-microscopic pathologic changes were present any transferred mice, and results could not be reproduced.
Dose-dense doxorubicin and cyclophosphamide (ddAC) followed by dose-dense paclitaxel (ddP) (ddAC-P) has improved disease-free survival of patients with breast cancer. The aim this study was to evaluate the safety relative dose intensity (RDI) ddAC-P administered together pegfilgrastim.Between May 2015 Aug 2017, 44 were retrospectively reviewed; they 4 cycles ddAC, ddP. Pegfilgrastim (3.6 mg) in every cycle.The mean RDIs for ddAC-P, ddP 95.0%, 94.5%, 93.3%, respectively. prevalence high...
e12022 Background: PCP is rare complication of ddAC-ddP. DEX plausible risk factor for PCP. Dose and duration against CINV changing over time as other anti-emetic drugs (5HT3 RA, NK1 olanzapin) became available. Then usage varies widely in each hospitals. ASCO/IDSA guideline recommends preventive ST patients receiving 20 mg or more predonisone equivalents daily than one month, although evidence lacking This study to investigate relation between usage, ST, Methods: preplanned analysis...
e19634 Background: Oral mucositis (OM), which may decrease treatment effectiveness by dose reduction and impair the patient's quality of life, is thought to be a frequent complication associated with cancer chemotherapy. However, incidence severity OM induced chemotherapy in patient various solid tumor hematological malignancies unclear. The purpose this study determine it's sequelae patients receiving conventional for clarify risk factors OM. Methods: 227 (male 33%, female 66%) who received...
Abstract Purpose Data on the desire for pregnancy and status of fertility preservation (FP) in patients with breast cancer remains unclear. This study aimed to determine under 43 years age who desired FP implementation before systemic therapy. Methods retrospective surveyed institutional clinical databases electronic medical records < stage 0-III primary at time surgery treated between April 2020 March 2021. All were enquired about their a questionnaire by ‘present,’ ‘absent,’ ‘unsure’...
Abstract Background: The addition of a CDK4/6 inhibitor (CDK4/6i) on endocrine therapies (ET) has been currently standard treatment for hormone receptor (HR)-positive HER2-negative metastatic breast cancers (MBCs). Especially abemaciclib implicated in multiple mechanisms action including cell cycle arrest, senescence. In addition, immunomodulatory effects have suggested but are not yet clear. aim the study was to investigate clinical relevance systemic immune status by examining peripheral...